Cancer And Rare Diseases Top EU Drug Approvals In 2015
This article was originally published in Scrip
- 46 new active substances approved
- First stem cell therapy
- First drug for mitochondrial dysfunction
- 12 new anticancers
- 16 drugs for rare diseases
- Five accelerated approvals
- Four conditional approvals
- Three exceptional circumstances approvals
- Second-highest number of CHMP recommendations
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.